168 related articles for article (PubMed ID: 27490162)
1. TIOtropium Safety and Performance In Respimat
Zhong N; Moon HS; Lee KH; Mahayiddin AA; Boonsawat W; Isidro MG; Bai C; Mueller A; Metzdorf N; Anzueto A
Respirology; 2016 Nov; 21(8):1397-1403. PubMed ID: 27490162
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
[TBL] [Abstract][Full Text] [Related]
3. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
4. Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR
Anzueto A; Calverley PMA; Mueller A; Metzdorf N; Haensel M; Jardim JR; Pizzichini E; Giraldo H; Ramirez-Venegas A; Giugno ER
Arch Bronconeumol (Engl Ed); 2018 Mar; 54(3):140-148. PubMed ID: 29317111
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of tiotropium Respimat versus HandiHaler in patients naive to treatment with inhaled anticholinergics: a post hoc analysis of the TIOSPIR trial.
Wise R; Calverley PM; Dahl R; Dusser D; Metzdorf N; Müller A; Fowler A; Anzueto A
NPJ Prim Care Respir Med; 2015 Nov; 25():15067. PubMed ID: 26540491
[TBL] [Abstract][Full Text] [Related]
7. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR
Wise RA; Calverley PM; Carter K; Clerisme-Beaty E; Metzdorf N; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289
[TBL] [Abstract][Full Text] [Related]
8. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
[TBL] [Abstract][Full Text] [Related]
9. Comparative Effectiveness of Two Tiotropium Formulations: A Retrospective Cohort Study.
Spila-Alegiani S; Trotta F; Da Cas R; Rossi M; Venegoni M; Traversa G
COPD; 2018 Oct; 15(5):418-423. PubMed ID: 30822243
[TBL] [Abstract][Full Text] [Related]
10. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
12. Development of an enhanced health-economic model and cost-effectiveness analysis of tiotropium + olodaterol Respimat® fixed-dose combination for chronic obstructive pulmonary disease patients in Italy.
Selya-Hammer C; Gonzalez-Rojas Guix N; Baldwin M; Ternouth A; Miravitlles M; Rutten-van Mölken M; Goosens LM; Buyukkaramikli N; Acciai V
Ther Adv Respir Dis; 2016 Oct; 10(5):391-401. PubMed ID: 27405723
[TBL] [Abstract][Full Text] [Related]
13. Tiotropium versus ipratropium bromide for chronic obstructive pulmonary disease.
Cheyne L; Irvin-Sellers MJ; White J
Cochrane Database Syst Rev; 2015 Sep; 2015(9):CD009552. PubMed ID: 26391969
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Tang Y; Massey D; Zhong NS
Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
[TBL] [Abstract][Full Text] [Related]
15. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.
Wise RA; Anzueto A; Calverley P; Dahl R; Dusser D; Pledger G; Koenen-Bergmann M; Joseph E; Cotton D; Disse B
Respir Res; 2013 Apr; 14(1):40. PubMed ID: 23547660
[TBL] [Abstract][Full Text] [Related]
16. The Effect of Defining Chronic Obstructive Pulmonary Disease by the Lower Limit of Normal of FEV
Calverley PMA; Mueller A; Fowler A; Metzdorf N; Wise RA
Ann Am Thorac Soc; 2018 Feb; 15(2):200-208. PubMed ID: 28957643
[TBL] [Abstract][Full Text] [Related]
17. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
[TBL] [Abstract][Full Text] [Related]
18. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
Verhamme KM; Afonso A; Romio S; Stricker BC; Brusselle GG; Sturkenboom MC
Eur Respir J; 2013 Sep; 42(3):606-15. PubMed ID: 23520322
[TBL] [Abstract][Full Text] [Related]
19. The lung function profile of once-daily tiotropium and olodaterol via Respimat(®) is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler(®) (ENERGITO(®) study).
Beeh KM; Derom E; Echave-Sustaeta J; Grönke L; Hamilton A; Zhai D; Bjermer L
Int J Chron Obstruct Pulmon Dis; 2016; 11():193-205. PubMed ID: 26893551
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy and safety of tiotropium Respimat in the treatment of chronic obstructive pulmonary disease: systematic review].
Cai HD; Hou J; Lyu YN; Xiong L; Lu MZ; Wu SL
Zhonghua Jie He He Hu Xi Za Zhi; 2017 Aug; 40(8):596-603. PubMed ID: 28810313
[No Abstract] [Full Text] [Related]
[Next] [New Search]
